Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...
The global veterinary vaccines market is projected to grow from USD 11 billion in 2025 to USD 15.6 billion by 2031, ...
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 millionUniquely structured, flexible ...
Creative Biogene is a dedicated research solutions provider focused on developing cutting-edge platforms for cancer therapy and preclinical studies. The team of seasoned scientists, bioinformatics ...
Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases
Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through ...
At ASCO 2026, oral abstract presenters highlighted new and exciting central nervous system (CNS) tumour treatments.
FOXO Technologies Inc. (OTC: FOXO) (the “Company”) and LongevityFP Technologies, LLC. (“LFP”) today jointly announced a strategic partnership to commercialize the Company’s pioneering epigenetics ...
It's quick to spot a tick, but harder to know if that tick carries Lyme disease. Emergency room visits for tick bites provide ...
Australia’s first dedicated RNA Research and Manufacturing Facility has officially opened at the Macquarie University ...
TP motor insurance premiums grew 9.3 percent during FY26, marginally ahead of the 9 percent growth recorded in the OD segment ...
“We can probably edit almost any gene, but that doesn’t mean we should,” Dan Rosan, chief financial and business officer of Ascidian Therapeutics, told Fierce Biotech. That thinking has shaped how the ...
Jefferies Global Healthcare Conference 2026 June 4, 2026 3:10 PM EDTCompany ParticipantsAlexandria Forbes - CEO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results